Emily Leonard is the vice-chair of the firm's Life Sciences Industry Group and a member of the corporate and intellectual property practice groups. She is resident in the firm’s Silicon Valley office.
Ms. Leonard concentrates in transactions for pharmaceutical and biotechnology clients, with an emphasis on complex strategic partnering and collaboration agreements, joint ventures, licensing and other technology transfer arrangements. She also advises clients ranging from early-stage ventures to large public and private companies with respect to the full range of clinical and commercial agreements that span the life cycle of a drug product or medical device, including technology evaluation, sponsored research, clinical study, clinical research organization, professional services, manufacturing and co-promotion agreements. Her early years at the firm also included experience in all facets of civil litigation, including second-chairing a three-week jury trial in which the jury returned a defense verdict for Covington's client in a defamation case, as well as representation of white collar and other defendants in criminal investigations and proceedings.
- Astellas in a global alliance with Medivation to develop and commercialize a Phase 3 investigational drug for the treatment of prostate cancer, which involved an up-front cash payment of $110 million, up to $655 million in development and commercial milestone payments and a US co-promotion option based on profit sharing (nominated as a candidate for Alliance Deal of the Year (In Vivo Blog 2009)); and in a global licensing arrangement with Ambit to develop and commercialize a Phase 2 kinase inhibitor for acute myeloid leukemia, which involved a $40 million up-front payment, up to $350 million in pre-commercialization milestones, and a US co-promotion option based on profit sharing.
- AstraZeneca in a strategic collaboration with Map Pharmaceuticals to develop and commercialize a Phase 3 product for the treatment of asthma, which involved upfront fees, milestones and funding commitments in excess of $900 million and a co-promotion option; and in a strategic collaboration with Abbott to develop and commercialize a fixed-dose combination therapy for cholesterol management.
- Biosynexus in its reacquisition of rights to its lead antibody product for the treatment of staph infections in premature infants.
- Gilead in a series of transactions with two multinational pharmaceutical companies concerning the development and commercialization of a combination antiretroviral drug, including various corporate and contractual arrangements for supply and distribution in the United States, the European Union, and the access countries.
- Institute of OneWorld Health, a non-profit pharmaceutical company, in the negotiation of collaboration and other agreements for the advancement and commercialization of drug products for neglected diseases, particularly those that disproportionately affect developing world countries.
- Medarex in a strategic alliance with a Japanese pharmaceutical company, involving the cross license of platform technologies consisting of transgenic and transchromosomic mouse technologies, and in connection with a number of other collaboration agreements concerning antibody products.
Honors and Rankings
- Chambers USA, recognized for Life Sciences/Commercial (2007-2013)
Legal 500 US, Healthcare: Life Sciences and Media, Technology & Telecoms (2013)
- Northern California Super Lawyers, Intellectual Property (2013)
- The Daily Journal, Top Women Lawyers (2011)
- PLC Which Lawyer? Life sciences: Commercial and Partnering (USA) (2008-2012)
- LMG Life Sciences, "Life Science Star" (2013)
Publications and Speeches
- Ms. Leonard is a speaker on issues affecting the Life Sciences industry in the United States, including structuring and negotiating complex collaboration and joint venture arrangements. She has chaired a number of conferences on these issues in the last several years.